Clinical Research on Selank in Anxiety Disorders: Insights From Russian Trials

Introduction
In a clinical study conducted by Syunyakov et al. (2012), the synthetic heptapeptide Selank was examined for its effects in patients diagnosed with generalized anxiety disorder (GAD). Selank has previously been described in the scientific literature as an anxiolytic agent with additional stimulatory and cognitive-enhancing properties. While earlier studies had demonstrated its overall anxiolytic activity, the researchers noted that the time required for patients to respond to treatment varied considerably, and this variability had not been systematically investigated prior to their work.
Study Objective
The study carried out by Syunyakov and colleagues aimed to analyze individual patterns of treatment response in Selank-treated patients with GAD. Specifically, the researchers sought to compare changes in clinical symptom severity and electroencephalographic (EEG) activity between patients who exhibited rapid improvement and those who demonstrated a more gradual response to treatment.
Methods
According to the methodology described by Syunyakov et al., the study enrolled 20 adult patients between 24 and 52 years of age who met DSM-IV diagnostic criteria for generalized anxiety disorder. Selank was administered intranasally at a total daily dose of 2700 micrograms. The researchers assessed clinical outcomes using validated anxiety rating instruments, including the Hamilton Anxiety Rating Scale (HARS). To evaluate neurophysiological effects, the study incorporated pharmaco-EEG measurements, allowing the investigators to observe changes in brain electrical activity following Selank administration.
Findings
The researchers identified two distinct response patterns among participants. In the study population, 40% of patients were classified as rapid responders, as reported by Syunyakov et al., showing a pronounced reduction across the full spectrum of anxiety symptoms within the first one to three days of treatment. In this group, mean HARS scores decreased significantly by day 3. The remaining 60% of patients were described as conventional responders, demonstrating a more gradual improvement, with statistically significant reductions in anxiety severity achieved by day 14.
Neurophysiological data reported in the study indicated clear differences between these two groups. Syunyakov and colleagues observed that rapid responders exhibited a marked EEG reaction following a single Selank dose, characterized by increased beta-rhythm activity and decreased theta and low-frequency alpha rhythms. These EEG changes were less pronounced in conventional responders. Additionally, baseline clinical assessments revealed that rapid responders initially presented with higher levels of asthenic and cognitive symptoms compared with conventional responders.
Conclusion
Based on the findings reported by Syunyakov et al. (2012), the study confirms that Selank treatment in patients with generalized anxiety disorder is associated with significant individual variability in therapeutic response. The presence of a subgroup exhibiting rapid clinical improvement, combined with distinct EEG reactivity and symptom profiles, suggests that neurophysiological and clinical characteristics may influence response patterns. The researchers concluded that these observations underscore the importance of individualized assessment in the study of peptide-based anxiolytic compounds.

Important Notice
This content is provided for educational and informational purposes only. The research discussed relates exclusively to laboratory and scientific investigation. No claims are made regarding biological activity, therapeutic use, or outcomes. Compounds referenced are not intended for human or veterinary use.

Sources
Syunyakov T. et al. (2012). Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank. European Psychiatry.